social linkedin box blue 32
social facebook box blue 32
social twitter box blue 32
social facebook box blue 32


Notizie & Eventi ■ Notizie ■ Notizie 2010

Notizie 2010

Alberto Diaspro launches Nanoscale Biophysics Subgroup at 2011 Biophysical Society

The IIT is pleased to announce that Alberto Diaspro launches the Nanoscale Biophysics Subgroup and Program at the 2011 Biophysical Society Meeting.

To learn more visit:

Ultimo aggiornamento Mercoledì 08 Dicembre 2010

Synthesis, Structural Characterization and Modeling of the Growth of Colloidal Nanocrystals

Earlier this year Liberato Manna, Head of Nanochemistry gave a talk at the at the 2010 RBNI (Russel Berrie Nanotechnology Institute) winter school at Ein Gedi in Israel. The talk can be considered as a general introduction to the fabrication of nanostructures by colloidal chemical approaches.

Ultimo aggiornamento Martedì 15 Febbraio 2011

Doctoral school Humanoid & Life Technologies XXVI Cycle

Vengono pubblicate le graduatorie di ammissione ai corsi “Nanosciences”, "Robotics" e "Drug Discovery" della Scuola di dottorato di ricerca – XXV Ciclo – denominata “Life and Humanoid Technologies” (Tecnologie Umanoidi e della Vita).

Seleziona qui per vedere il testo del bando.


Ultimo aggiornamento Mercoledì 01 Dicembre 2010

Ground breaking study by D3 published in Nature Neuroscience

Potential first-in-class compound reveals new approach to the treatment of pain

 A new study has shown how a novel compound boosts levels of a natural painkiller at the site of an injury. The ground-breaking study published today in Nature Neuroscience shows how the potential drug URB937 acts in peripheral tissue and may have the potential to relieve pain without the side effects associated with many current painkillers that act centrally on the nervous system.

The preclinical study by the Drug Discovery and Development (D3) unit of the Istituto Italiano di Tecnologia and the University of California, showed that URB937, a potent, second-generation inhibitor of the enzyme fatty acid amide hydrolase (FAAH), controlled pain and inflammation locally at site by boosting levels of anandamide in peripheral tissues, part of the analgesic and anti-inflammatory endocannabinoid system. The compound is the first FAAH inhibitor produced with restricted access to the central nervous system (CNS), whereas current FAAH inhibitors readily cross the blood-brain barrier.1

Dr Daniele Piomelli, Scientific Director of D3, and lead investigator said: “These findings are significant because they show for the first time how FAAH inhibitors may enable the body to harness its own analgesic and anti-inflammatory powers right where the pain relief is needed and avoid side effects often seen in other painkillers. This has great potential to give patients more treatment options to relieve a wide spectrum of pain, such as rheumatoid arthritis and peripheral neuropathic pain.”

By circumventing the CNS, the compound may have numerous therapeutic advantages over current pain treatments such as opiates and non-steroidal anti-inflammatory drugs (NSAIDs) that can cause unwanted side effects in some patients such as nausea, bowel irritation and dependency.2, 3

Andrew Rice, Professor of Pain Research at Imperial College London, said: “This paper represents an important advance in the development of clinically useful cannabinoids. The existing laboratory and clinical data unequivocally demonstrate that cannabinoids have pain relieving properties, but their therapeutic index needs to be improved. By using a strategy of inhibiting an enzyme which inactivates endogenous cannabinoid only outside the brain and showing that this approach is still sufficient to retain an analgesic effect, Professor Piomelli and his colleagues have made a significant advance.”

D3 is continuing the development programme of URB937 and plans to begin clinical studies in 2012.

Investigators from other institutions were also involved in the study, including the universities of Urbino, Parma, Naples, and the Complutense University in Madrid.


About the D3

The D3 is a specialist unit of the Istituto Italiano di Tecnologia dedicated to the discovery of new medicines. The organisation focuses its research efforts on drug discovery in the three key therapeutic areas of pain, inflammation and dementia. By collaborating with private partners, the D3 brings together excellence in basic science from academia with the focus of the pharmaceutical industry to accelerate research in important areas of unmet medical need. Funded by the Italian government, the D3 will employ over 70 scientists and technical staff by December 2010. The organisation’s state-of-the-art facilities include 2000m2 of laboratory and office space completed in December 2009. For more information, visit


About the IIT

The Istituto Italiano di Tecnologia (IIT) is a foundation established jointly by the Italian Ministry of Education, Universities and Research and the Ministry of Economy and Finance to promote excellence in basic and applied research and to contribute to the economic development of Italy. The primary goals of the IIT are the creation and dissemination of scientific knowledge as well as the strengthening of Italy's technological competitiveness. To achieve these two goals, the IIT will cooperate with both academic institutions and private organisations, fostering through these partnerships scientific development, technological advances and training in high technology. For more information visit 


About the University of California, Irvine

Founded in 1965, UCI is a top-ranked university dedicated to research, scholarship and community service. Led by Chancellor Michael Drake since 2005, UCI is among the most dynamic campuses in the University of California system, with nearly 28,000 undergraduate and graduate students, 1,100 faculty and 9,000 staff. Orange County’s largest employer, UCI contributes an annual economic impact $3.9 billion. For more UCI news, visit


1.     Schlosburg, J.E., Kinsey, S.G. & Lichtman, A.H. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J. 11, 39-44 (2009)

2.     Hochman JS, Shah NR. What price pain relief? Circulation. 2006 Jun 27; 113(25):2868-70. Epub 2006 Jun 19. Erratum in: Circulation. 2006 Aug 22; 114(8):e364.

3.     Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003 Aug; 74(2):102-12.

Ultimo aggiornamento Domenica 28 Novembre 2010

Roberto Cingolani è il vincitore della terza edizione del premio “Grande Ippocrate per il ricercatore medico dell’anno"


Genova, 15 novembre 2010 - Viene conferito oggi a Roberto Cingolani, Direttore scientifico dell’Istituto Italiano di Tecnologia, il Premio Grande Ippocrate 2010. Promosso da Unamsi e Novartis, il premio intende valorizzare quei ricercatori italiani che, oltre ad eccellere nell’attività medico-scientifica, si distinguono nel saperne divulgare i risultati.

“La giuria ha scelto di premiare Roberto Cingolani – dichiara Francesco Brancati, Presidente Unamsi - per essere riuscito a coniugare la complessa attività di ricerca nell’ambito delle nanotecnologie applicate alla medicina e alla salute dell’uomo, con l’impegno nella divulgazione scientifica al grande pubblico, offrendo costante disponibilità e collaborazione ai rappresentanti dei media".

ll Premio Grande Ippocrate è stato istituito nel 2008 grazie alla collaborazione tra UNAMSI - Unione Nazionale Medico Scientifica d'Informazione, cui aderiscono circa 80 giornalisti professionisti e pubblicisti specializzati in campo medico - e Novartis che crede nell’importanza di promuovere una corretta e trasparente divulgazione e comunicazione scientifica.

Il comunicato stampa è disponibile qui (Italiano)

Ultimo aggiornamento Lunedì 22 Novembre 2010


Il sito web di IIT utilizza i seguenti tipi di cookies: di navigazione/sessione, analytics, di funzionalità e di parti terze. L’utente può scegliere di acconsentire all’uso dei cookies e accedere al sito.
Facendo click su maggiori informazioni verrà visualizzata l’informativa estesa sui tipi di cookies utilizzati e sarà possibile scegliere se autorizzare i cookies durante la navigazione sul sito.

Prova il nostro nuovo sito ed esprimi la tua opinione
Vai al nuovo sito